LP352
Phase 3Small molecule
LP352 is one of 15 small molecule programs targeting Dravet syndrome. It is currently in Phase 3.
2
Indications
5
Total Trials
3
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Dravet Syndrome
#DrugCompanyPhaseTrials
1Epidiolex
Jazz PharmaceuticalsPhase 3
Sympazan
LundbeckPhase 3
Lorcaserin
EisaiPhase 3
Soticlestat
TakedaPhase 3
Calan
VVal Adams
Phase 2
Translarna
PPTC Therapeutics
Phase 2
GWP42003-P
Jazz PharmaceuticalsPhase 2
LP352
LLongboard Pharmaceuticals
Phase 3
Clemizole Hcl
EEpygenix
Phase 3
Zorevunersen
SStoke Therapeutics, Inc
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Developmental and Epileptic Encephalopathy1 trial
Children1 trial
Dravet syndrome1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LP352. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- LLongboard Pharmaceuticals